Multicenter, Prospective, Open-label, Single-arm Phase IIIb/IV Clinical Study on the Safety of Photodynamic Therapy With Porfimer Sodium for Injection for the Ablation of High-grade Dysplasia in Barrett's Esophagus.

Trial Profile

Multicenter, Prospective, Open-label, Single-arm Phase IIIb/IV Clinical Study on the Safety of Photodynamic Therapy With Porfimer Sodium for Injection for the Ablation of High-grade Dysplasia in Barrett's Esophagus.

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 07 May 2012

At a glance

  • Drugs Porfimer sodium (Primary)
  • Indications Barrett's oesophagus; Oesophageal cancer
  • Focus Adverse reactions
  • Acronyms OEDISSE
  • Sponsors Pinnacle Biologics
  • Most Recent Events

    • 07 May 2012 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 07 May 2012 Last checked against ClinicalTrials.gov record.
    • 08 Jun 2011 Planned end date changed from 1 Mar 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top